Filtered By:
Condition: Arrhythmia
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 249 results found since Jan 2013.

Individualized approaches to thromboprophylaxis in atrial fibrillation
Publication date: March 2016 Source:American Heart Journal, Volume 173 Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in persons older than 55 years is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart rate control, and heart rhythm control comprise the 3 main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism, and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antagonist such as ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
Purpose Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. The main objective of Effectiveness, Safety and Costs in Atrial Fibrillation (ESC-FA) study is to analyse the drugs used for the management of the disease in real-use conditions, particularly the antithrombotic agents for stroke prevention. The aim of this work is to present the study protocol of phase I of the ESC-FA study and the baseline characteristics of newly dia...
Source: BMJ Open - January 28, 2016 Category: Journals (General) Authors: Giner-Soriano, M., Vedia Urgell, C., Roso-Llorach, A., Morros, R., Capella, D., Castells, X., Ferreira-Gonzalez, I., Troncoso Marino, A., Diogene, E., Elorza, J. M., Casajuana, M., Bolibar, B., Violan, C. Tags: Open access, Cardiovascular medicine, Epidemiology, Health services research, Pharmacology and therapeutics Cohort profile Source Type: research

Study: Medtronic touts increased AF detection with Reveal Linq system
Medtronic (NYSE:MDT) today released 1-year results from a study of patients who experienced a cryptogenic stroke, claiming that its Reveal Linq insertable cardiac monitor was able to detect atrial fibrillation at a greater rate than previously reported in a 2014 clinical trial. Results from the real-world study were presented at the 68th American Academy of Neurology’s annual meeting in Vancouver, Canada. The Reveal Linq device is designed to be implanted beneath the skin on the upper left side of the chest and is indicated for monitoring patients experiencing dizziness, palpitation, fainting or syncope, chest pain ...
Source: Mass Device - April 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials Patient Monitoring Medtronic Source Type: news

Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH – AFNET 6) trial
Conclusion NOAH – AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial high rate episodes detected by implanted devices. Graphical abstract
Source: American Heart Journal - May 4, 2017 Category: Cardiology Source Type: research

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non –vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
Conclusion NOAH–AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial high rate episodes detected by implanted devices. Graphical abstract
Source: American Heart Journal - May 24, 2017 Category: Cardiology Source Type: research

The SAFIRA study: A reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects
Conclusions This study shows the high prevalence of AF in the elderly population, as well as suboptimal rates of diagnosis, anticoagulation and effective control of cardiovascular risk factors.
Source: Revista Portuguesa de Cardiologia - April 24, 2018 Category: Cardiology Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
CONCLUSIONS: This meta-analysis showed that the evidence is uncertain to inform the decision to either interrupt or continue anticoagulation therapy around CA procedure in adults with arrhythmia on outcomes of thromboembolic events, major and minor bleeding, all-cause mortality, asymptomatic thromboembolic events, and a composite endpoint of thromboembolic events (stroke, systemic embolism, major bleeding, and all-cause mortality). Most studies in the review adopted a minimal interruption strategy which has the advantage of reducing the risk of bleeding while maintaining a lower level of anticoagulation to prevent periproc...
Source: Cochrane Database of Systematic Reviews - October 21, 2021 Category: General Medicine Authors: Ghada A Bawazeer Hadeel A Alkofide Aya A Alsharafi Nada O Babakr Arwa M Altorkistani Tarek S Kashour Michael Miligkos Khalid M AlFaleh Lubna A Al-Ansary Source Type: research

Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
Conclusion In this nationwide cohort study of patients ≥75 years initiating oral anticoagulation for AF, standard and reduced dose NOACs were associated with similar risks of stroke/SE as warfarin and lower or similar risks of bleeding. The NOACs seem to be a safe option also in elderly patients.
Source: Heart - February 16, 2022 Category: Cardiology Authors: Rutherford, O.-C. W., Jonasson, C., Ghanima, W., Söderdahl, F., Halvorsen, S. Tags: Open access Arrhythmias and sudden death Source Type: research

Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
ConclusionsEarly AF ablation in a contemporary prospective cohort of AF patients who were predominantly treated with NOACs was associated with a survival advantage compared to medical therapy alone.Trial registrationClinical trial registration:http://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007 and NCT01937377.Graphical abstractCreated with BioRender.com.
Source: Clinical Research in Cardiology - April 29, 2022 Category: Cardiology Source Type: research

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Conclusion Betrixaban was well tolerated and had similar or lower rates of bleeding compared with well-controlled warfarin in patients with AF at risk for stroke.
Source: European Heart Journal - May 21, 2013 Category: Cardiology Authors: Connolly, S. J., Eikelboom, J., Dorian, P., Hohnloser, S. H., Gretler, D. D., Sinha, U., Ezekowitz, M. D. Tags: Arrhythmia/electrophysiology Source Type: research

Moving Beyond Warfarin-Are We Ready?: A Review of the Efficacy and Safety of Novel Anticoagulant Agents Compared to Warfarin for the Management of Atrial Fibrillation in Older Adults.
Abstract Atrial fibrillation (AF) is one of the most common cardiac arrhythmias seen in clinical practice. Stroke risk in patients diagnosed with AF increases from 1.5% in the fifth decade of life to 23.5% in patients older than 80, emphasizing the need for effective and appropriate therapies. Over the past 50 years, vitamin K antagonists-namely warfarin (Coumadin(®))-have been the mainstay for stroke prevention. The introduction of dabigatran (Pradaxa(®)), rivaroxaban (Xarelto(®)), and apixaban (Eliquis(®)) has caused both patients and providers to question whether better alternatives to warfarin therapy exis...
Source: Journal of Gerontological Nursing - June 12, 2013 Category: Nursing Authors: Ogbonna KC, Clifford KM Tags: J Gerontol Nurs Source Type: research

Antiplatelet Therapy in Japanese Patients with Atrial Fibrillation without Oral Anticoagulants: Pooled Analysis of Shinken Database, J-RHYTHM Registry and Fushimi AF Registry
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke. Oral anticoagulants (OAC) are effective for stroke prevention in patients with AF, and recent evidences have revealed the efficacy and safety of non-vitamin K antagonist OAC (NOAC) as well as warfarin. Although aspirin was shown to be inferior to warfarin or apixaban in preventing stroke [1,2], it is still prescribed to many AF patients in clinical practice [3–5]. This may be because physicians perceived it to be a safer and more convenient alternative to OAC.
Source: International Journal of Cardiology - April 22, 2015 Category: Cardiology Authors: Hisashi Ogawa, Masaharu Akao, Shinya Suzuki, Takeshi Yamashita, Ken Okumura, Hirotsugu Atarashi, Hiroshi Inoue Tags: Letter to the Editor Source Type: research